Skip to main content
SpringerLink
Log in

First-Trimester Nuchal Translucency Screening in Pregnant Women Who Subsequently Developed Gestational Diabetes

  • Published:
The Journal of the Society for Gynecologic Investigation: JSGI Aims and scope Submit manuscript

Abstract

Objective

To compare the nuchal translucency (NT) thickness at 11—14 weeks of gestation in women who will later develop gestational diabetes mellitus (GDM) with that of women with normal glucose tolerance (NGT) in the second trimester of pregnancy.

Methods

Four hundred sixty four women underwent NT screening at 11—14 weeks of gestation according to the standards of the Fetal Medicine Foundation. They all underwent an oral glucose tolerance test (OGTT) between 24 and 28 weeks.

Results

Women with GDM (n = 135) were significantly older (34.0 years [±4.8] vs 29.4 years [±5.2]; P <.001), had a significantly higher body mass index (BMI) (28.2 kg/m2[±6.0] vs 24.4 [±5.0]; P <.001), and had a significantly higher serum concentration of hemoglobin A1c(HbA1c) at the time of the NT measurement (5.38% [±0.6] vs 4.95% [±0.4]; P <.001] than women with NGT (n = 329). There is no significant difference in the NT measurement at 11 to 14 weeks of gestation between women with GDM and NGT after correction for crown rump length (CRL) (r = —.08, P =.45). We performed multiple linear regression analysis with NT as the dependent variable, and BMI, maternal age, CRL, and GDM/NGT as independent variables. CRL (P <.001) was significantly related to the NT measurement, whereas GDM/NGT, BMI, and maternal age were not.

Conclusion

AS no significant difference in the NT measurement between women with GDM and NGT was observed, the risk estimation for chromosomal abnormality derived from the maternal age and NT measurement can also be used in women with glucose disorders.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hafiner E, Schuchter K, Liebhart E, Philipp K. Results of routine fetal nuchal translucency measurement at weeks 10–13 in 4233 unselected pregnant women. Prenat Diagn 1998;18:29–34.

    Article  Google Scholar 

  2. Snijders RJ, Noble P, Sebire N, Souka A, Nicolaides KH. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10–14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group. Lancet 1998;352-343–346.

    Article  CAS  Google Scholar 

  3. Nicolaides KH. Nuchal translucency and other first-trimester songraphic markers of chromosomal abnormalities. Am J Obstet Gynecol 2004;191:45–67.

    Article  Google Scholar 

  4. Yamashita T, Mimura K, Umeda F, Kobayashi K, Hashimoto T, Nawata H. Increased transendothelial permeation of albumin by high glucose concentration. Metabolism 1995;44:739–744.

    Article  CAS  Google Scholar 

  5. Van der Meulen JA, Klip A, Grinstein S. Possible mechanism for cerebral oedema in diabetic ketoacidosis. Lancet 1987;2:306–308.

    Article  Google Scholar 

  6. Bleicher SJ, Lee TY, Bernstein R, Schachter L, Temes R, Krupin T, et al. Effect of blood glucose control on retinal vascular permeability in insulin-dependent diabetes mellitus. Diabetes Care 1980;3:184–186.

    Article  CAS  Google Scholar 

  7. Carpenter MW, Canick JA, Hogan JW, Shellum C, Somers M. Star JA. Amniotic fluid insulin at 14–20 weeks’ gestation: association with later maternal glucose intolerance and birth macrosomia. Diabetes Care 2001;24:1259–1263.

    Article  CAS  Google Scholar 

  8. Dashora U, Dashora V, Kennedy L. Two-hour 75-g oral glucose tolerance test early in pregnancy detects most cases of gestational diabetes. Diabetes Care 2002;25:803–803.

    Article  Google Scholar 

  9. Nicolaides KH, Azar G, Byrne D, Mansur C, Marks K. Fetal nuchal translucency: ultrasound screening for chromosomal defects in first trimester of pregnancy. BMJ 1992;304:867–869.

    Article  CAS  Google Scholar 

  10. American Diabetes Association. Gestational diabetes mellitus. Diabetes Care 2004;27:s88–s90.

    Article  Google Scholar 

  11. Sepe SJ, Connell FA, Geiss LS, Teutsch SM. Gestational diabetes. Incidence, maternal characteristics, and perinatal outcome. Diabetes 1985;34 Suppl. 2:13–16.

    Article  Google Scholar 

  12. Kalkhoff RK, Richardson BL, Beck P. Relative effects of pregnancy, human placental lactogen and prednisolone oncarbohydrate tolerance in normal and subclinical diabetic subjects. Diabetes 1969;18:153–163.

    Article  CAS  Google Scholar 

  13. Landgraf R, Landraf-Leurs MM, Weissmann A, Horl R, von Werder K, Scriba PC. Prolactin: A diabetogenic hormone. Diabetologia 1977;13:99–104.

    Article  CAS  Google Scholar 

  14. Sutter-Dub MT, Dazey B, Vergnaud MT, Made AM. Progesterone and insulinresistance in the pregnant rat. I. In vivo and in vitro studies. Diabetes Metab 1981:7:97–104.

    CAS  Google Scholar 

  15. Carpenter MW. Metabolic changes in gestational diabetes. Clin Perinatol 1993;20:583–591.

    Article  CAS  Google Scholar 

  16. Keller J, Krohmer JS. Insulin transfer in the isolated human placenta. Obstet Gynecol 1968;32:77–80.

    CAS  PubMed  Google Scholar 

  17. Bartha JL, Wood J, Kyle PM, Soothill PW. The effect of metabolic control on fetal nuchal translucency in women with insulin-dependent diabetes: A preliminary study. Ultrasound Obstet Gynecol 2003;21:451–454.

    Article  CAS  Google Scholar 

  18. Narchi H, Kulaylat N. High incidence of Down’s syndrome in infants of diabetic mothers. Arch Dis Child 1997;77:242–244.

    Article  CAS  Google Scholar 

  19. Jovanovic L, Peterson CM. Screening for gestational diabetes. Optimum timing and criteria for retesting Diabetes 1985;34 Suppl. 2:21–23.

    Article  Google Scholar 

  20. Kurishita M, Nakashima K, Kozu H. Glycated hemoglobin of fractionated erythocytes, glycated albumin, and plasmafructosamine during pregnancy. Am J Obstet Gynecol 1992;167:1372–1378.

    Article  CAS  Google Scholar 

  21. Bartha JL, Martinez-Del-Fresno P, Comino-Delgado R. Gestational diabetes mellitus diagnosed during early pregnancy. Am J Obstet Gynecol 2000;182:346–350.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynaecology, University of Vienna Medical School, Waehringer Guertel 18-20, A-1090, Vienna, Austria

    Heinz Leipold MD, Christof Worda MD, Aral Özbal MD, Peter Husslein MD & Elisabeth Krampl MD

Authors
  1. Heinz Leipold MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christof Worda MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Aral Özbal MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Peter Husslein MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Elisabeth Krampl MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christof Worda MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Leipold, H., Worda, C., Özbal, A. et al. First-Trimester Nuchal Translucency Screening in Pregnant Women Who Subsequently Developed Gestational Diabetes. Reprod. Sci. 12, 529–532 (2005). https://doi.org/10.1016/j.jsgi.2005.05.003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1016/j.jsgi.2005.05.003

Key words

Search

Navigation